The post Blue Jays’ John Schneider Sends Message On Trade Deadline Fire Sale appeared on BitcoinEthereumNews.com. LOS ANGELES, CALIFORNIA – OCTOBER 29: ManagerThe post Blue Jays’ John Schneider Sends Message On Trade Deadline Fire Sale appeared on BitcoinEthereumNews.com. LOS ANGELES, CALIFORNIA – OCTOBER 29: Manager

Blue Jays’ John Schneider Sends Message On Trade Deadline Fire Sale

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

LOS ANGELES, CALIFORNIA – OCTOBER 29: Manager John Schneider #14 of the Toronto Blue Jays looks on before game five of the 2025 World Series against the Los Angeles Dodgers at Dodger Stadium on October 29, 2025 in Los Angeles, California. (Photo by Luke Hales/Getty Images)

Getty Images

The Toronto Blue Jays are hovering around a losing record, just a few months after reaching Game 7 of the World Series.

The poor record has come as a surprise following that Fall Classic run last year as well as a blockbuster offseason of roster additions. But with significant injuries to key players like Alejandro Kirk, Cody Ponce and Shane Bieber, the Blue Jays have been unable to meet the rising expectations for success.

“For two months now, manager John Schneider has been patching holes,” Keegan Matheson wrote for MLB.com. “No two lineups have looked the same, a daily game of figuring out who’s still healthy and who fits where.”

ForbesBlue Jays’ Former Pitcher Finds New Home After Brutal Game Leads To Phillies Cut

Toronto Blue Jays Lean On Players Acquired During Trade Deadline Fire Sale

And as Schneider gets creative with the team’s lineups, he’s been leaning on a collection of younger players who were acquired during the team’s disappointing trade deadline fire sale from two seasons ago.

“With the Jays promoting infield prospect Charles McAdoo on Thursday, though, their 2024 trade deadline haul continues to bear fruit,” Mitch Bannon noted for The Athletic. ‘McAdoo becomes the fourth current Jay with ties to that August sell-off, with others close behind. The franchise’s worst season in the last six years is now somehow keeping the 2026 team’s hopes alive.”

The Blue Jays cut ties with veterans Yusei Kikuchi, Justin Turner and Isiah Kiner-Falefa when it became clear that they had fallen out of contention two years ago. And while that might have been a disappointment to fans, the younger pieces that the team got back in exchange are now playing some key roles.

In addition to McAdoo, Yohendrick Pinango and Brandon Valenzuela were acquired during that fire sale. And outfielder Jesus Sanchez was also an indirect result of those transactions, as he was added in exchange for Will Wagner and Joey Loperfido, who were acquired back then.

Further down the organization, additional pieces acquired at that trade deadline like Jake Bloss, RJ Schreck and Jonatan Clase could be next in line for the big-league roster as the Blue Jays look to stay afloat amid the injuries.

ForbesGiants’ Rafael Devers Makes Agency Change After Trade Report

Toronto Blue Jays Manager John Schneider Sends Message On Successful Trade Deadline Reset

If the Blue Jays do indeed survive the worst of their injury setbacks and make another deep playoff run this year thanks to these younger pieces, it will officially turn that painful fire sale into a success story for the franchise.

“I think that’s kind of how we planned it,” Schneider said of now reaping the rewards of that selloff, per Bannon, “in a year where it didn’t go the way we wanted to here.”

Source: https://www.forbes.com/sites/peterchawaga/2026/05/31/blue-jays-john-schneider-sends-message-on-trade-deadline-fire-sale/

Market Opportunity
Polytrade Logo
Polytrade Price(TRADE)
$0.03905
$0.03905$0.03905
+0.46%
USD
Polytrade (TRADE) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage